The appetite for next generation breast cancer therapies continues to grow unabated.
The biotech sector has been taking a beating during the volatility this week as investors sell-off assets for fear of compounding the risk factors of the choppy market and the characteristically
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Website: | www.macrogenics.com |
Email: | info@macrogenics.com |
Main Phone: | +1 301 251-5172 |
Address: | 9704 Medical Center Drive |
State: | MD |
City / Town: | Rockville |
Country: | US |
Postal Code: | 20850 |
Exchange: | NGS |
CEO: | Scott Koenig |
Employees: | 370 |
NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The appetite for next generation breast cancer therapies continues to grow unabated.
The biotech sector has been taking a beating during the volatility this week as investors sell-off assets for fear of compounding the risk factors of the choppy market and the characteristically
Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
Open N/A | High N/A | Low N/A | Prev Close N/A |
Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |